Integra Lifesciences Analyst Price Targets

Integra Lifesciences Holdings Corp

IARTNASDAQ

Trade with Public

$13.21

-0.32-2.37%

마지막 업데이트: Oct 16, 4:00 PM

$13.21

-0.32-2.37%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

실적: Q3 2026 실적이 수 10월 21st에 개장 전 3일 후 후에 발표됩니다.

컨퍼런스 콜: 3일 후 8:30 오전에 컨퍼런스 콜이 예정되어 있습니다.

웹캐스트를 보려면 클릭하세요.

Integra Lifesciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Integra Lifesciences (IART).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

2S.Buy

1Buy

6Hold

3Sell

Consensus RatingMarket Outperform# Analysts12Avg. Consensus PT$21Upside to Avg. PT+61.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 14, 2026	Truist Securities	Ravi Misra	PT Cut	Hold	$19→$15
Oct 5, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$19→$15
Oct 5, 2026	BMO Capital	Vik Chopra	PT Cut	Market Perform	$18→$15
Jul 30, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$15→$18
Jul 28, 2026	UBS	Patrick Wood	Initiate	Neutral	$19
Jul 16, 2026	Truist Securities	Ravi Misra	PT Raise	Hold	$14→$19
Jul 9, 2026	BMO Capital	Vik Chopra	Initiate	Market Perform	$19
Jul 8, 2026	Citigroup	Joanne Wuensch	PT Raise	Neutral	$16→$19
May 28, 2026	Citigroup	Joanne Wuensch	Upgrade	Sell→Neutral	$11→$16
May 6, 2026	Citigroup	Joanne Wuensch	PT Raise	Sell	$9→$11
May 6, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$12→$15
Apr 15, 2026	Truist Securities	Ravi Misra	PT Cut	Hold	$13→$12
Apr 15, 2026	Argus Research	David Toung	Downgrade	Buy→Hold	—
Mar 11, 2026	Citigroup	Joanne Wuensch	PT Cut	Sell	$11→$9
Feb 27, 2026	Wells Fargo	Vik Chopra	PT Cut	Equal-Weight	$13→$12
Nov 3, 2025	Truist Securities	Ravi Misra	PT Cut	Hold	$15→$13
Oct 31, 2025	Citigroup	Joanne Wuensch	PT Cut	Sell	$12→$11
Oct 31, 2025	JP Morgan	Robbie Marcus	PT Raise	Underweight	$12→$13
Oct 15, 2025	Truist Securities	Richard Newitter	PT Raise	Hold	$13→$15
Oct 7, 2025	Citigroup	Joanne Wuensch	PT Raise	Sell	$10→$12

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $19 to $15.

Benzinga Newsdesk

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $18 to $15.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and raises the price target from $15 to $18.

Benzinga Newsdesk

PRO
UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral rating and announces Price Target of $19.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price target from $14 to $19.

Benzinga Newsdesk

PRO
BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19

BMO Capital analyst Vik Chopra initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Market Perform rating and announces Price Target of $19.

Benzinga Newsdesk

Integra Lifesciences Holdings Corp

Integra Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

PRO
UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

PRO
BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19

뉴스

파트너 / 기고자

벤징가 글로벌

Integra Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

PRO
UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

PRO
BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19

People Also Watch

People Also Watch

Integra Lifesciences Holdings Corp

Integra Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTruist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

PROBMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

PROWells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

PROUBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

PROTruist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

PROBMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19

뉴스

파트너 / 기고자

벤징가 글로벌

Integra Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTruist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

PROBMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

PROWells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

PROUBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

PROTruist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

PROBMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19

People Also Watch

People Also Watch

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

PRO
UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

PRO
BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

PRO
UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

PRO
BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19